[ALS Association](https://www.als.org)

November 2026 (Letter of Intent) | February 2027 (Full proposal)

Up to $1,000,000 per award over 2–3 years, milestone-driven.

Supports early-stage, biomarker-driven ALS clinical trials (phase 1 or 2a) to accelerate therapy development and de-risk further drug development.

--- ## Description The Hoffman ALS Clinical Trial Awards Program is designed to accelerate the development of new and improved therapies for amyotrophic lateral sclerosis (ALS) by funding early-stage clinical trials. The focus is on phase 1 or phase 2a, biomarker-driven trials that generate essential data on safety, dosing, and biomarkers, which are critical for advancing investigational therapies toward FDA evaluation. The program also supports trials of imaging tracers and encourages the testing of innovative or repurposed interventions, including small molecules, genetic therapies, stem cell approaches, peptides, antibodies, and antisense therapies. Projects may include participants with ALS, healthy subjects, and/or asymptomatic carriers. --- ## Due Dates - **November 2026 (anticipated):** Letter of Intent deadline - **February 2027 (anticipated):** Full proposal deadline *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - **Award Size:** Up to $1,000,000 per project - **Project Duration:** 2 to 3 years, with funding allocated based on achievement of milestones - **Indirect Costs:** Generally limited to 10% of the total award amount --- ## Eligibility - **Who can apply:** - Academic and industry researchers, including those from U.S. and non-U.S. institutions. - Both established and early-career investigators are welcome (except junior postdoctoral fellows, unless applying to a different ALS Association fellowship program). - Applicants are expected to have the skills, knowledge, and resources necessary to complete the proposed project. - **Eligible projects:** - Early-stage (phase 1 or 2a), biomarker-driven clinical trials for ALS or imaging tracers. - Interventions may include disease-modifying or symptomatic agents (small molecules, genetic therapies, stem cells, peptides, antibodies, antisense therapies, etc.). - Must include relevant participant groups (ALS patients, healthy controls, or asymptomatic carriers). - **Other requirements:** - Applicants may hold multiple active ALS Association awards. - Proposals must align with the program’s mission and scope. --- ## Application Process - **Submission Platform:** All materials must be submitted via [ProposalCentral](https://proposalcentral.com/) - **Process:** 1. **Letter of Intent (LOI):** 3–4 pages describing the biology, intervention, trial design, biomarker strategy, and commercialization plan. 2. **Full Proposal (by invitation):** ~14 pages detailing the scientific plan, research team, budget, and business plan. 3. **Review:** LOIs are reviewed for program alignment; selected applicants are invited to submit full proposals, which are peer-reviewed by external experts. 4. **Final Approval:** Proposals recommended by reviewers are considered by the ALS Association’s Research Committee for final funding decisions. - **Reporting:** Awardees must submit progress reports every six months and annual expenditure reports via ProposalCentral. --- ## Additional Information - **Allowable Costs:** Personnel (with restrictions on PI salary if indirect costs are claimed), supplies, equipment (with caps), travel, and publication costs. - **Unallowable Costs:** PI salary (if indirect costs are not waived), permanent equipment, excessive travel, tuition, and costs exceeding specified limits (see [Grants Policy Statement](http://www.als.org/Grants-Policy-Statement)). - **No-cost extensions:** May be requested for up to 6 months (with possible second extension in exceptional cases). - **Rebudgeting:** Allowed up to 10% of total award without pre-approval. --- ## External Links - [Program Overview and Details](https://www.als.org/hugh-and-herbert-hoffman-als-impact-fund/hoffman-als-clinical-trial-awards-program) - [ALS Association Research Funding Opportunities](https://www.als.org/research/researchers/research-funding-opportunities) - [Information for Grant Applicants and Awardees](https://www.als.org/research/researchers/information-grant-applicants-and-awardees) - [Grants Policy Statement](http://www.als.org/Grants-Policy-Statement) --- ## Contact Information | Purpose | Contact | |------------------------|----------------------------------------------| | General Inquiries | [alsinfo@als.org](mailto:alsinfo@als.org) | | Research Grants Team | [ResearchGrants@als.org](mailto:ResearchGrants@als.org) | | Phone | +1 800-782-4747 | | Contact Form | [ALS Association Contact Page](https://www.als.org/contact-us) |

The Hoffman ALS Clinical Trial Awards Program

Sign in to see full grant listing